Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs

Advanced Drug Delivery Reviews

Volumn 24, Issue 2-3, 1997, Pages 225-231

  Storm, Gert ^a   Vingerhoeds, Monique H ^a   Crommelin, Daan J A ^a   Haisma, Hidde J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADEPT; antibody directed enzyme prodrug therapy; immunoliposomes; liposomes; monoclonal antibody; targeted drug delivery

Indexed keywords

ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; BINDING ENERGY; CELLS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; DRUG THERAPY; ENZYME KINETICS; IMMUNOLOGY; LIPIDS;

ACTIVATING ANTHRACYCLINE PRODRUGS; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTICANCER PRODRUGS; CHEMOTHERAPY; HUMAN CANCER; IMMUNOLIPOSOME; TARGET CELL BINDING;

PHARMACOKINETICS;

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; CHOLESTEROL; DAUNORUBICIN; ENZYME; EPIRUBICIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; N [4 (4 MALEIMIDOPHENYL)BUTYRYL]PHOSPHATIDYLETHANOLAMINE; N SUCCINIMIDYL S ACETYLTHIOACETATE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PRODRUG; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER THERAPY; CLEARANCE; CONFERENCE PAPER; DRUG BINDING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; OVARY CARCINOMA; PRIORITY JOURNAL; TARGET CELL; TUMOR LOCALIZATION;

EID: 0343923458     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00461-9     Document Type: Conference Paper

References (23)

1. Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 58, 700-703.
2. Deonarain, M.P. and Epenetos, A.A. (1994) Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer. 70, 786-794.
3. Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.L., Brown, J.P., Hellström, I. and Hellström, K.E. (1988) Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA, 85, 4842-4846.
4. Senter, P.D., Wallace, P.M., Svensson, H.P., Vrudhula, V.M., Kerr, D.E., Hellström, I. and Hellström, K.E. (1993) Genera tion of cytotoxic agents by targeted enzymes. Bioconj. Chem., 4, 3-9.
5. Bagshawe, K.D., Sharma, S.K., Springer, C.J. and Antoniw, P. (1995) Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting, 1, 17-29.
6. Vingerhoeds, M.H., Haisma, H.J., van Muijen, M., van de Rijt, R.B.J., Crommelin, D.J.A. and Storm, G. (1993) A new application for liposomes in cancer therapy: immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett., 336, 485-490.
7. Heeremans, J.L.M., Prevost, R., Los, P., Kluft, C. and Crommelin, D.J.A. (1995) Fibrin binding glu-plasminogen coated liposomes in vitro. Thromb. Haemost., 75, 134-139, 1996.
8. Vingerhoeds, M.H., Steerenberg, P.A., Hendriks, J.J.G.W., Dekker, L.C., Van Hoesel, Q.G.C.M., Crommelin, D.J.A. and Storm, G. (1996) Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer, 74, 1023-1029.
9. Storm, G., Nässander, U.K., Vingerhoeds, M.H., Steerenberg, P.A. and Crommelin, D.J.A. (1994) Antibody-targeted liposomes to deliver doxorubicin to ovarian cancer cells. J. Liposome Res., 4, 641-666.
10. Nässander, U.K., Steerenberg, P.A., Poppe, H., Storm, G., Poels, L.G., De Jong, W.H. and Crommelin, D.J.A. (1992) In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res., 52, 646-653.
11. Martin, F.J. and Papahadjopoulos, D. (1982) Irreversible coupling of immunoglobulin fragments to preformed vesicles. J. Biol. Chem., 257, 286-288.
12. Jousma, H., Talsma, H., Spies, F., Joosten, J.G.H., Junginger, H.E. and Crommelin, D.J.A. (1987) Characterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayers. Int. J. Pharm., 35, 263-274.
13. Vingerhoeds, M.H., Haisma, H.J., Belliot, S.O., Smit, R.H.P., Crommelin, D.J.A. and Storm, G. (1996) Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm. Res., 13, 604-610.
14. Haisma, H.J., Boven, E., van Muijen, M., de Jong, J., van der Vijgh, W.J.F. and Pinedo, H.M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer, 66, 474-478.
15. Leenders, R.G.G., Gerrits, K.A.A., Ruijtenbeek, R., Scheeren, H.W., Haisma, H.J. and Boven, E. (1995) β-Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPT. Tetrahedon Lett., 36, 1701-1704.
16. Haisma, H.J., van Muijen, M., Pinedo, H.M. and Boven, E. (1994) Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys., 24/25, 185-192.
17. Vingerhoeds, M.H., Storm, G. and Crommelin, D.J.A. (1994) Immunoliposomes in vivo (review). ImmunoMethods, 4, 259-272.
18. Dutton, G.J. (1966) Glucuronic Acid Free and Combined. Academic Press, New York.
19. Fishman, W.H. (1970) Metabolic Conjugation and Metabolic Hydrolysis. Academic Press, New York.
20. Alving, C.R. (1992) Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta, 1113, 307-322.
21. Storm, G., Oussoren, C., Peeters, P.A.M. and Barenholz, Y. (1993) Tolerability of liposomes in vivo. In: G. Gregoriadis (Ed.), Liposome Technology, Vol. III, 2nd edn., CRC Press, Boca Raton, FL, pp. 345-383.
22. Maruyama, K., Holmberg, E., Kennel, S.J., Klibanov, A., Torchilin, V.P. and Huang, L. (1990) Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J. Pharm. Sci., 79, 978-984.
23. Ledermann, J.A., Begent, R.H.J., Bagshawe, K.D., Riggs, S.J., Searle, F., Glaser, M.G., Green, A.J. and Dale, R.G. (1988) Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br. J. Cancer, 58, 654-657.